Presentation is loading. Please wait.

Presentation is loading. Please wait.

REFLEX and REFLEXION study design.

Published byReino Heino Modified over 6 years ago

Similar presentations

Presentation on theme: "REFLEX and REFLEXION study design."— Presentation transcript:

1 REFLEX and REFLEXION study design.
REFLEX and REFLEXION study design. Short arrows indicate conversion to CDMS and the consequent switch to open-label treatment, which could happen at any time throughout the study. CDMS, clinically definite multiple sclerosis; IFN, interferon; MS, multiple sclerosis; qw, once weekly; REFLEX, REbif FLEXible dosing in early MS; REFLEXION, REbif FLEXible dosing in early MS extension; sc, subcutaneous; tiw, three times weekly. Giancarlo Comi et al. J Neurol Neurosurg Psychiatry 2017;88: ©2017 by BMJ Publishing Group Ltd

Download ppt "REFLEX and REFLEXION study design."

Similar presentations

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol
Figure 1 Clinical correlates of neurodegeneration in MS

Figure 1 Clinical correlates of neurodegeneration in MS
Sensory neuronopathy caused by dorsal root ganglionitis showing a hypercellular cluster of lymphocytes (nodule of Nageotte) indicating active neuronophagia.

Sensory neuronopathy caused by dorsal root ganglionitis showing a hypercellular cluster of lymphocytes (nodule of Nageotte) indicating active neuronophagia.
Figure 1 Evolution of multiple sclerosis

Figure 1 Evolution of multiple sclerosis
Figure 2 Primary and secondary outcomes reported in multiple sclerosis (MS) disease-modifying therapy (DMT) clinical trials Primary and secondary outcomes.

Figure 2 Primary and secondary outcomes reported in multiple sclerosis (MS) disease-modifying therapy (DMT) clinical trials Primary and secondary outcomes.
(A) This 54 year old man with the flail arm syndrome has severe wasting of the arms causing profound weakness. (A) This 54 year old man with the flail.

(A) This 54 year old man with the flail arm syndrome has severe wasting of the arms causing profound weakness. (A) This 54 year old man with the flail.
Figure 1 MOR103 sequential-dose trial flowchart of study population with multiple sclerosis aPatients received 2 doses of study drug before trial withdrawal.

Figure 1 MOR103 sequential-dose trial flowchart of study population with multiple sclerosis aPatients received 2 doses of study drug before trial withdrawal.
(A) EEG of a 75 year old woman with adult onset myoclonic epilepsy (see text, case 1), showing generalised spike and wave and polyspike and wave discharges.

(A) EEG of a 75 year old woman with adult onset myoclonic epilepsy (see text, case 1), showing generalised spike and wave and polyspike and wave discharges.
 Pseudoptosis.  Pseudoptosis. This man presented with photophobia and difficulty elevating the right side of his forehead. The photograph shows his normal.

 Pseudoptosis.  Pseudoptosis. This man presented with photophobia and difficulty elevating the right side of his forehead. The photograph shows his normal.
Photograph of the legs of a patient with inherited erythromelalgia, showing erythema to the level of the mid-calf. Photograph of the legs of a patient.

Photograph of the legs of a patient with inherited erythromelalgia, showing erythema to the level of the mid-calf. Photograph of the legs of a patient.
Figure 5 Increased B cell-activating factor (BAFF) levels are shared between immunomodulatory treatments Increased B cell-activating factor (BAFF) levels.

Figure 5 Increased B cell-activating factor (BAFF) levels are shared between immunomodulatory treatments Increased B cell-activating factor (BAFF) levels.
Photograph of the legs of a patient with inherited erythromelalgia, showing erythema to the level of the mid-calf. Photograph of the legs of a patient.

Photograph of the legs of a patient with inherited erythromelalgia, showing erythema to the level of the mid-calf. Photograph of the legs of a patient.
Cortical right hemisphere brain regions that have been associated with neglect include the angular (ang) and supramarginal (smg) gyri of the inferior parietal.

Cortical right hemisphere brain regions that have been associated with neglect include the angular (ang) and supramarginal (smg) gyri of the inferior parietal.
An example from a carotid surgery trial showing how an intention to treat analysis is less biased than an on-treatment analysis. An example from a carotid.

An example from a carotid surgery trial showing how an intention to treat analysis is less biased than an on-treatment analysis. An example from a carotid.
 Schematic representation of the early M response from the distally propagated action potential and the later F wave from the proximally propagated action.

 Schematic representation of the early M response from the distally propagated action potential and the later F wave from the proximally propagated action.
Figure Avidity of IgG specific for influenza A and B following flu vaccinationAvidity of immunoglobulin (Ig) G specific for influenza A and B before and.

Figure Avidity of IgG specific for influenza A and B following flu vaccinationAvidity of immunoglobulin (Ig) G specific for influenza A and B before and.
Figure 1 Peripheral blood lymphocyte counts during dose titrationB-lymphocyte (CD19+; A) and total lymphocyte (CD45+; B) counts (cells/µL) in peripheral.

Figure 1 Peripheral blood lymphocyte counts during dose titrationB-lymphocyte (CD19+; A) and total lymphocyte (CD45+; B) counts (cells/µL) in peripheral.
Figure 1. MBP-specific IFN-γ+ but not IL-17+ frequencies are significantly different between patients with MS and HCs MBP-specific IFN-γ+ but not IL-17+

Figure 1. MBP-specific IFN-γ+ but not IL-17+ frequencies are significantly different between patients with MS and HCs MBP-specific IFN-γ+ but not IL-17+
Autofluorescence left eye (case 3)

Autofluorescence left eye (case 3)
ACR20 response rates. ACR20 response rates. ACR20 response rates based on non-responder imputation (NRI) for the 120/Q4W, 90/Q2W and placebo groups over.

ACR20 response rates. ACR20 response rates. ACR20 response rates based on non-responder imputation (NRI) for the 120/Q4W, 90/Q2W and placebo groups over.

Similar presentations

Ads by Google